Skip to main content
. 2020 Mar 28;12(4):306. doi: 10.3390/pharmaceutics12040306

Figure 5.

Figure 5

IOP % profile of the following formulations: (▲) Marketed formulation (TM 0.5%), (●) TMGNP3 (0.1%), (×) TMGNP3 (0.1%) + HPMC 0.3% and (■) blank gelatin nanoparticles used as control.